
April 30 (Reuters) - Immunic Inc IMUX.O:
IMMUNIC ANNOUNCES VIDOFLUDIMUS CALCIUM REDUCED RISK OF DISABILITY WORSENING BY 30% IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS FROM PHASE 2 CALLIPER TRIAL
IMMUNIC INC - 20% REDUCTION IN DISABILITY WORSENING EVENTS IN STUDY POPULATION
IMMUNIC INC - FAVORABLE SAFETY PROFILE CONFIRMED, NO NEW SAFETY SIGNALS